Medicamen Biotech Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Medicamen Biotech's earnings have been declining at an average annual rate of -0.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 7.8% per year. Medicamen Biotech's return on equity is 3.2%, and it has net margins of 4.5%.
Wichtige Informationen
-0.4%
Wachstumsrate der Gewinne
-3.0%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 17.5% |
Wachstumsrate der Einnahmen | 7.8% |
Eigenkapitalrendite | 3.2% |
Netto-Marge | 4.5% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Medicamen Biotech Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 1,804 | 81 | 313 | 0 |
31 Mar 24 | 1,793 | 109 | 335 | 0 |
31 Dec 23 | 1,707 | 127 | 286 | 0 |
30 Sep 23 | 1,597 | 133 | 262 | 0 |
30 Jun 23 | 1,497 | 154 | 227 | 0 |
31 Mar 23 | 1,409 | 148 | 218 | 0 |
31 Dec 22 | 1,250 | 137 | 198 | 0 |
30 Sep 22 | 1,220 | 137 | 178 | 0 |
30 Jun 22 | 1,210 | 143 | 159 | 0 |
31 Mar 22 | 1,154 | 149 | 156 | 0 |
31 Dec 21 | 1,139 | 158 | 136 | 0 |
30 Sep 21 | 1,142 | 150 | 123 | 0 |
30 Jun 21 | 1,125 | 140 | 97 | 0 |
31 Mar 21 | 1,127 | 121 | 96 | 0 |
31 Dec 20 | 1,150 | 110 | 97 | 0 |
30 Sep 20 | 1,174 | 116 | 100 | 0 |
30 Jun 20 | 1,222 | 123 | 97 | 0 |
31 Mar 20 | 1,255 | 133 | 101 | 0 |
31 Dec 19 | 1,353 | 136 | 90 | 0 |
30 Sep 19 | 1,241 | 124 | 85 | 0 |
30 Jun 19 | 1,210 | 123 | 79 | 0 |
31 Mar 19 | 1,227 | 120 | 86 | 0 |
31 Dec 18 | 1,187 | 110 | 94 | 0 |
30 Sep 18 | 1,229 | 117 | 97 | 0 |
30 Jun 18 | 1,183 | 108 | 91 | 0 |
31 Mar 18 | 1,115 | 101 | 99 | 0 |
31 Dec 17 | 1,045 | 94 | 100 | 0 |
30 Sep 17 | 962 | 81 | 95 | 0 |
30 Jun 17 | 912 | 65 | 75 | 0 |
31 Mar 17 | 825 | 52 | 71 | 0 |
31 Dec 16 | 782 | 58 | 55 | 0 |
30 Sep 16 | 723 | 26 | 52 | 0 |
30 Jun 16 | 673 | 18 | 54 | 0 |
31 Mar 16 | 673 | 5 | 61 | 0 |
31 Dec 15 | 679 | -13 | 137 | 0 |
30 Sep 15 | 667 | -2 | 137 | 0 |
30 Jun 15 | 760 | -1 | 65 | 0 |
31 Mar 15 | 779 | 4 | 68 | 0 |
31 Dec 14 | 816 | 0 | 129 | 0 |
30 Sep 14 | 807 | -1 | 126 | 0 |
30 Jun 14 | 738 | -1 | 57 | 0 |
31 Mar 14 | 732 | 1 | 123 | 0 |
31 Dec 13 | 696 | -7 | 125 | 0 |
Qualität der Erträge: 531146 has high quality earnings.
Wachsende Gewinnspanne: 531146's current net profit margins (4.5%) are lower than last year (10.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 531146's earnings have declined by 0.4% per year over the past 5 years.
Beschleunigtes Wachstum: 531146's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 531146 had negative earnings growth (-47.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 531146's Return on Equity (3.2%) is considered low.